Trump officials reverse course, restore funding for women's health study
The study, called the Women's Health Initiative (WHI), was launched by the National Institutes of Health (NIH) in 1991 to learn about women's specific health needs since medical studies before then used mainly men.
WHI researchers at the initiative's four regional centers were notified this week that the Department of Health and Human Services (HHS) would be terminating their contracts in September.
The White House ordered HHS in early April to cut contract spending by 35 percent to make sure the department was using its funding efficiently.
But HHS's decision to end the decades-old initiative's financial backing quickly received pushback from researchers and lawmakers alike.
HHS Secretary Robert F. Kennedy Jr. posted to X to say the reports of the initiative's funding freeze were 'fake news' and that WHI would continue to be financed by the department.
'We are not terminating the study. NIH Director Dr. Jay Bhattacharya has himself used this study in his own research. We all recognize that this project is mission critical for women's health,' he wrote on X.
An HHS spokesperson confirmed to The Hill that the department is currently working on restoring funding to the study so that its 'essential research' not be interrupted.
'NIH remains deeply committed to advancing public health through rigorous gold standard research and we are taking immediate steps to ensure the continuity of these studies,' the spokesperson said.
More than 160,000 women signed up to take part in WHI's clinical studies in the mid-90s and there are more than 40,000 women who have taken part in the study initiative for decades.
WHI's clinical studies have resulted in better treatment for women with conditions like cardiovascular disease and breast cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Federal cuts force families to make difficult, and potentially deadly, choices
A mother rushes into the emergency department cradling her 6-month-old baby. He is lethargic, seizing and in critical condition. The cause? Severely low sodium levels in his blood — a result of formula diluted with extra water to make it last longer. With grocery prices climbing and her SNAP benefits running out before the end of the month, she felt she had no other choice. This story is not an outlier. Pediatric clinicians across Wisconsin are seeing the real and devastating consequences of policies that fail to prioritize the health and well-being of children and families. And now, the situation could get worse. The Trump Administration's proposed 'skinny' budget for Fiscal Year 2026 includes deep and dangerous cuts to federal programs that form the backbone of public health in our communities. These proposed reductions include: $18 billion from the National Institutes of Health – stalling critical pediatric research and innovation $3.5 billion from the Centers for Disease Control and Prevention – compromising disease surveillance, immunization programs, and emergency response efforts $1.73 billion from the Health Resources and Services Administration – cutting access to essential primary and preventive care services for children and families $674 million from the Centers for Medicare & Medicaid Services – threatening the Medicaid and CHIP programs that provide health coverage to nearly half of Wisconsin's children. Opinion: We asked readers about wake boats on Wisconsin lakes. Here's what you said. And as if that weren't enough, further reductions to SNAP and other nutrition support programs are also on the table. These aren't just numbers on a spreadsheet. These are lifelines. Vital services that help children survive and thrive. When families can't afford formula, when clinics lose funding for immunization programs, when children lose health coverage, the consequences are immediate and, in many cases, irreversible. As front-line providers, we witness this every day. We can do better. Our federal budget is a reflection of our national values. It should not balance its books on the backs of our youngest and most vulnerable. I implore Wisconsin's elected officials to reject this harmful budget proposal. Think of that infant in the emergency room. Think of the thousands of other children across our state whose health and future depend on robust public health infrastructure, access to care, and support for families in need. We urge lawmakers to work toward a bipartisan budget that invests in children, strengthens public health, and protects the building blocks of a healthy society. Wisconsin's children deserve every opportunity to grow up healthy and strong. Our chapter of the National Association of Pediatric Nurse Practitioners stands ready to partner in this effort. Let's move forward — not backward — when it comes to the health of our children. Christine Schindler is a critical care pediatric nurse practitioner at Children's WI, a clinical professor at Marquette University, and the President of the Wisconsin Chapter of Pediatric Nurse Practitioners. She has been caring for critically ill and injured children for almost 30 years. All opinions expressed are her own. This article originally appeared on Milwaukee Journal Sentinel: Trump budget jeopardizes health of American children | Opinion
Yahoo
2 hours ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
Newsweek
3 hours ago
- Newsweek
The Bulletin June 4, 2025
The rundown: Health and Human Services Secretary Robert F. Kennedy Jr.'s vow to "Make America Healthy Again" could fall short when it comes to chronic disease, experts have warned. Here's how. Why it matters: Nearly 130 million Americans are estimated to have at least one form of chronic disease, which could be heart disease, cancer, diabetes, obesity or hypertension, according to the Centers for Disease Control and Prevention. The proposed cuts to Medicaid funding and work requirements for eligibility to the benefits, which are set to come as part of the broader GOP budget bill, could leave many with chronic disease without access to vital care. As many as three in four adults enrolled in Medicaid report having one or more chronic conditions, and many are unable to work the hours needed to meet the new eligibility requirements, according to nonprofit health policy research and news organization, KFF. So, while some may be medically exempt, others will lose their health coverage, meaning their conditions could worsen without access to care. Read more in-depth coverage: Health Experts Call Out RFK Jr. Policy Changes: 'New Inconsistency Every Day' TL/DR: Experts told Newsweek that, while the Trump administration's ambition to "defeat" the "epidemic" is clear, whether its policies will help or hinder chronic-disease patients remains to be seen. What happens now? Ross Brownson, director of the Prevention Research Center at Washington University in St. Louis, Missouri, told Newsweek that Medicaid cuts would "likely have a detrimental effect on chronic disease risk among the most vulnerable populations," adding Medicaid-enrolled adults have significantly higher rates of chronic disease than individuals privately insured. Deeper reading Can Trump Tackle US 'Chronic Disease Crisis'? Experts Weigh In
